Our Take
Novo beat Lilly to oral approval in two major markets, but the real constraint is NHS reimbursement—not regulatory clearance.
Why it matters
Oral GLP-1s are reshaping obesity treatment accessibility, and approval timing now determines market share. The UK's private waitlist already signals demand far exceeds supply.
Do this week
Healthcare operators: audit your GLP-1 supply contracts this week to confirm whether Wegovy oral is listed or tirzepatide dependency locks you into higher acquisition costs.
Novo's oral Wegovy clears UK regulator; Lilly still waiting
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk's oral semaglutide (Wegovy) for adults with obesity (BMI 30+) and overweight patients with BMI 27–30 and at least one weight-related comorbidity. The once-daily tablet contains the same active ingredient as the weekly injection and delivers similar efficacy: patients lose just under 14% of body weight over 64 weeks (company-reported).
Novo now leads Eli Lilly in oral obesity approvals across two key markets. In the US, Novo's oral Wegovy launched in May 2026 and accumulated more than three million prescriptions by June, filling one prescription every five seconds over the five-month window (company calculation). Lilly's oral offering, Foundayo (orforglipron), remains approved only in the US.
The Wegovy pill is also recommended for approval in Europe. Dosing starts at 1.5mg daily and escalates to 4mg, 9mg, and 25mg; patients switching from the 2.4mg weekly injection can transition directly to the 25mg daily tablet.
NHS reimbursement is the real bottleneck—not regulatory approval
MHRA clearance does not guarantee access. The National Institute for Health and Care Excellence (NICE) has not yet conducted a cost-effectiveness review for oral Wegovy, and the injectable version is already highly restricted on the NHS. That gap has created immediate demand spillover into the private sector.
Simple Online Healthcare, a UK digital health platform, reports 55,000 patients on its waitlist for oral GLP-1 treatment. This is not speculative demand; it is concrete queue depth. Private prescription volume will signal true UK adoption and supply constraints before NICE's decision lands.
Novo's advantage over Lilly on efficacy (3% better average weight loss, per the company) matters less than manufacturing and dosing friction. Foundayo, a small molecule, has straightforward manufacturing and no meal restrictions. Wegovy, a peptide, must be taken on an empty stomach—a friction point for compliance and real-world uptake.
Secure supply contracts before NHS coverage is announced
If NICE approves Wegovy oral for NHS coverage, demand will spike and private channel capacity will shrink. Operators reliant on private GLP-1 prescriptions should lock multi-year tirzepatide or semaglutide supply agreements now, before reimbursement certainty drives inventory competition.
Separately, Novo disclosed that it was the subject of a cyber-attack in which certain non-public data, including personal data, was copied externally without authorisation. The company has taken certain IT systems offline and is investigating with external cybersecurity experts. This does not affect the approval itself but warrants monitoring for any supply-chain or data-handling delays.